摘要
目前我国医药行业正处于从低谷开始逐渐恢复的转型时期,医药并购市场也开始进入以资源整合为目的的修养生息阶段。医药行业发生大规模并购的内因是规模经济的发展要求行业集中度提高,外因是国家出台的一系列行业整顿政策与外资竞争压力促使行业内部进行整合以提高抵御能力。医药行业并购重组的结果是行业集中度得到提高,初步呈现寡头垄断和产业集群的局面,经济利润向优势企业集中,行业亏损面不断扩大。
Currently, Chinese medicinal industry is in the transformation period from the low valley to the road of gradual recovery, and the medicinal M＆A market begins to enter the recovery stage to accomplish the source integration. The internal cause of large-scale M＆A in medicinal industry is that the development of the scale economy requests an exaltation of integration. And the external cause is that a series of restructure policies from government in medicinal industry and the competition pressure from foreign capitals urge the internal integration to enhance the resistance ability. The result of M＆A in medicinal industry makes the industrial concentration degree be increased, the situation of the oligarch monopolization and the industrial cluster occur initially,the economic profits centralize towards the advantage enterprises, and the negative profit area of the industry be extended continuously.
出处
《科技情报开发与经济》
2006年第7期121-123,共3页
Sci-Tech Information Development & Economy
